Pharma — India Patent Cases
967 decisions indexed
Page 20 of 33 · 967 total
Sun Pharmaceutical Industries Ltd v.Jimsun Life Sciences P. Ltd & Anr.
The Delhi High Court allowed a petition filed by Sun Pharmaceutical Industries Ltd seeking the cancellation of the trademark 'JIMSUN' held by Jimsun Life Sciences P. Ltd. The court granted the relief based on a settlement reached between the parties, where Respondent No. 1 agreed to have no objection to the cancellation. This order effectively cleared the path for the Petitioner to remove the disputed mark from the registry.
Merck Sharp & Dohme Corp v.Sanjeev Gupta
The commercial suit for patent infringement concerning Sitagliptin (protected by IN 209816) was settled between Merck Sharp & Dohme Corp and Sanjeev Gupta & Ors. The Defendants acknowledged the validity of the patent and agreed to cease all infringing activities, including manufacturing generic versions, until the patent expires.
Merck Sharp & Dohme LLC v.Chiral Biosciences Limited
The suit was filed seeking a permanent injunction and damages against Chiral Biosciences Limited for infringing Merck Sharp & Dohme's patent (IN 209816) covering Sitagliptin. Although the court found evidence of infringement, it ultimately denied the permanent injunction because the patent had expired by July 2022, but awarded damages and costs.
Chugai Seiyaku Kabushiki Kaisha v.Hetero Labs Limited
The Plaintiffs filed a suit seeking permanent injunction and damages against the Defendants for infringing Indian Patent No. 294424, which covers the tetracyclic compound Alectinib used in cancer treatment. The dispute centered on whether the Defendant's import and use of Alectinib Hydrochloride were commercial infringements or activities permitted under Section 107A (Bolar provision) for research and regulatory purposes.
Natco Pharma Limited v.Union Of India & Ors.
Natco Pharma Limited filed a writ petition challenging an order by the Assistant Controller that refused its application seeking cross-examination during pre-grant opposition proceedings against Novartis A.G.'s patent application (No. 4412/DELNP/2007). The court ultimately disposed of the petition, allowing for procedural steps to be taken in the underlying opposition.
Boehringer Ingelheim International GmbH v.The Controller Of Patents & Anr.
Boehringer Ingelheim appealed the Controller's rejection of a divisional patent application related to DPP-IV inhibitors. The core dispute centered on whether the parent application contained a 'plurality of inventions' sufficient to support the new product claims sought in the divisional filing. The Delhi High Court ultimately rejected the appeal, holding that since the original application only contained method or use claims and not distinct product claims, the subsequent introduction of such products was considered disclaimed. Consequently, the divisional application could not proceed.
Astrazeneca Ab v.MSN Laboratories Limited
Astrazeneca filed a suit seeking permanent injunction and damages for infringing Indian Patent IN 297581 related to cancer treatment. The dispute centered on whether a Public Notice issued by the Department of Pharmaceuticals constituted Government Authorization allowing generic manufacturing. The Court clarified that the notice was merely for collating local manufacturer details, not an authorization to infringe.
Disruptive Health Solutions Private Limited v.Registrar Of Trade Marks
The Delhi High Court overturned a rejection of the trademark 'HEALTHSKOOL' by the Registrar, which had deemed it descriptive under Section 9(1)(b) of the Trade Marks Act. The court recognized that despite some indicia related to health, the mark was sufficiently distinctive given its long-standing use since 2015 and existing registrations in various classes. Consequently, the application was allowed to proceed for advertisement, albeit with a caveat preventing exclusive rights over the generic term 'Health'.
Novo Nordisk A S v.Union Of India
Novo Nordisk challenged an order by the Deputy Controller of Patents, arguing that the decision did not address the substantive grounds raised in its representation regarding a pending post-grant opposition. The case involves Patent IN257402, which relates to pharmaceutical preparations. Despite years of delays and procedural complexities in the Opposition Board proceedings, the High Court intervened to ensure that the Deputy Controller would consider all arguments presented by the patentee before rendering a final decision.
Novartis Ag v.MSN Laboratories Pvt Ltd
The petitioner filed an application alleging that the defendant violated a prior injunction by offering to supply Eltrombopag Olamine to the Government. The court examined whether this offer, made under Section 100 of the Patents Act, 1970, constituted contempt.
Sanjeev Khandelwal v.Ganesh Medicals
The plaintiff filed a suit alleging infringement of his patent (No. 197822) against three defendants. Subsequently, the parties executed a Deed of Compromise dated 22.11.2010. The court disposed of the suit based on this compromise.
Sanjeev Khandelwal v.Ganesh Medicals
The plaintiff filed a suit alleging infringement of his patents against three defendants. Subsequently, the parties executed a Deed of Compromise dated 22.11.2010. The court disposed of the suit in terms of this compromise, decreeing it against the third defendant and dismissing it against the first and second defendants.
XXX v.Union Of India
The petitioner, suffering from HER2-Negative Metastatic Breast Cancer, sought an interim direction compelling the 3rd respondent (DPIIT) to consider their representation regarding the high cost of Ribociclib. The petitioner argued that since Ribociclib enjoys patent monopoly and is not manufactured in India, compulsory licensing under Section 92 of the Patents Act, 1970, was necessary for affordability.
Sun Pharmaceutical Industries Ltd v.Union Of India & Ors.
The petitions were filed seeking directions to expedite the hearing and adjudication of a post-grant opposition against Patent No. IN 257402, which was facing significant delays by the Respondents (Controller/UOI). The Petitioner also challenged the validity of the Opposition Board's constitution and recommendation.
Chugai Seiyaku Kabushiki Kaisha & Anr. v.Natco Pharma Limited
Plaintiffs (Chugai Seiyaku Kabushiki Kaisha & Anr.) filed a suit seeking permanent injunction against Natco Pharma Limited for infringing Indian Patent No. 294424, which covers the tetracyclic compound Alectinib (Alecensa®). The dispute centered on the Defendant's alleged export and potential commercial launch of generic Alectinib products. The matter was amicably resolved.
Sun Pharmaceutical Industries Ltd v.Union of India
The petitioner filed writ petitions seeking directions to the respondents (Controller/UOI) to expedite the hearing and adjudication of a post-grant opposition against Patent No. IN 257402. The petitioner also challenged the validity of the Opposition Board's recommendation, alleging procedural flaws. The Court directed the Competent Authority to decide the pending representation and scheduled the patent proceedings.
Boehringer Ingelheim Pharma GmbH & Co. KG v.MSN Laboratories Private Limited
The applicants (Boehringer Ingelheim Pharma) filed applications seeking interim directions to restrain the respondents (MSN Laboratories and others) from infringing their patent rights over the medicinal product, Linagliptin. The court found that the defendants had not laid a credible challenge to the validity of the patent and tilted the balance of convenience in favor of the plaintiffs.
Boehringer Ingelheim Pharma GmbH & Co. KG v.MSN Laboratories Private Limited
The plaintiffs, Boehringer Ingelheim Pharma, filed applications seeking interim directions to restrain respondents from infringing their patent rights related to Linagliptin. The court found that the defendants had not presented a credible challenge to the patent's validity and tilted the balance of convenience in favor of the plaintiffs.
Boehringer Ingelheim Pharma GmbH & Co. KG v.MSN Laboratories Private Limited
The applicants (Boehringer Ingelheim) filed applications seeking interim directions against the respondents (MSN Laboratories and others) for alleged infringement of their patent covering the compound Linagliptin. The court found that the defendants had not laid any credible challenge to the validity of the patent, thus tilting the balance of convenience in favor of the plaintiffs.
Boehringer Ingelheim Pharma GmbH & Co. KG v.MSN Laboratories Private Limited
The plaintiffs, Boehringer Ingelheim Pharma, filed applications seeking interim directions against respondents (including MSN Laboratories and others) for infringing their patent rights related to the medicinal product Linagliptin. The court found that the defendants had not presented a credible challenge to the patent's validity and tilted the balance of convenience in favor of the plaintiffs.
MSN LABORATORIES PRIVATE LIMITED v.THE CONTROLLER OF PATENTS, BOUDHIK SAMPADA BHAVAN, DWARKA, SECTOR-32, PLOT 14 NEW DELHI-400037; BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
The plaintiff (MSN Laboratories) filed a petition seeking the revocation of Indian Patent No. IN 243301. The defendants argued that the petition was time-barred as it was filed more than three years after the patent grant date. The court dismissed the applications, holding that the limitation period for challenging a patent is not necessarily from the date of grant but when the right to sue accrues, and affirming its territorial jurisdiction.
Novartis Ag v.Centurion Remedies Private Limited
Novartis filed a suit seeking permanent injunction and damages against Centurion Remedies Private Limited for infringing Indian Patent No. 229051 concerning pharmaceutical compositions comprising Valsartan and NEP Inhibitors. The court clarified that the Department's Public Notice was merely to collate local manufacturers and did not constitute Government Authorization under Section 100 of the Patents Act, 1970. Consequently, the suit was decreed granting a permanent injunction against Centurion Remedies.
Novartis Ag v.Msn Laboratories Private Limited
Novartis filed a suit seeking permanent injunction and damages against MSN Laboratories for alleged infringement of Patent No. 283133 concerning Pyrrolopyrimidine compounds. The dispute also involved whether a public notice issued by the Department of Pharmaceuticals constituted government authorization to manufacture the patented drug, Ribociclib.
Novartis Ag v.Msn Laboratories Private Limited
Novartis filed a suit seeking permanent injunction against Msn Laboratories Private Limited for alleged infringement of Patent No. 237430 (Inhibitors of Tyrosine Kinases). The dispute centered on whether the Department of Pharmaceuticals' public notice constituted government authorization to manufacture the drug Nilotinib. The court, without considering the merits of infringement or validity, directed that Msn Laboratories must provide four weeks' advance notice before commencing commercial production.
Novartis Ag v.Centurion Remedies Private Limited
Novartis filed a suit seeking permanent injunction and damages against Centurion Remedies Private Limited for alleged infringement of Indian Patent No. 233161. The court examined the defendant's affidavit, which claimed no commercial activity related to the patented drug ELTROMBOPAG OLAMINE/ REVOLADE. Furthermore, the Department of Pharmaceuticals clarified that its public notice was merely for collating local manufacturers and did not constitute government authorization under Section 100 of the Patents Act, 1970.
Pfizer Inc And Ors v.Jodas Expoim Pvt Ltd And Anr
The court framed several issues in this commercial suit concerning alleged patent infringement by the defendants against Pfizer Inc and Ors. The core questions revolve around whether the defendants' activities infringe two specific Indian Patents (No. 218291 and No. 209251) and if the plaintiffs are entitled to permanent injunction or damages.
Merck Sharp And Dohme Corp v.Beaukev Pharma International Pvt. Ltd
Merck Sharp And Dohme Corp filed a suit seeking permanent injunction against Beaukev Pharma International Pvt. Ltd for infringing its registered patent (IN'816) related to Sitagliptin. The dispute was subsequently settled under the Delhi High Court Mediation and Conciliation Centre.
Astrazeneca Ab v.Msn Laboratories Limited
This order was passed in an interim application filed by the Plaintiffs (Astrazeneca Ab). The Defendant (MSN Laboratories Limited), through its counsel, requested a restraint on commercial launch while challenging the patent's validity and rights under Section 107(A) of the Patents Act, 1970.
Sun Pharmaceutical Industries Ltd v.Dwd Pharmaceuticals Ltd
The Delhi High Court granted an interim injunction favoring Sun Pharmaceutical Industries Ltd against Dwd Pharmaceuticals Ltd. The court found that the Defendant's use of the deceptively similar trademark 'FOLZEST' infringed upon the Plaintiff's registered mark 'FORZEST'. Recognizing the potential for irreparable harm, the court restrained the defendant from selling or manufacturing the infringing product until further hearing. Furthermore, a Local Commissioner was appointed to inspect and seize all medicines bearing the impugned mark.
Novartis Ag v.Msn Laboratories Pvt Ltd
The case involves a dispute over the infringement of a patent related to the drug Pazopanib Hydrochloride. The Plaintiff claims that the Defendant manufactured stock during the patent's lifetime, while the Defendant argues that they launched the product only after the patent expired.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.